About 68·8% of the SCMs opined that, if selection criteria are to be based on family history of cancer for HR+/HER2-negative eBC patients in resource-constrained settings, GT for BRCA germline pathogenic variants can be limited to patients with known likely/pathogenic variants in high-penetrance BC susceptibility genes (including BRCA1/2) in at least one close blood relative with BC diagnosed at age ≤50, epithelial ovarian non-mucinous cancer at any age, or high Gleason prostate cancer diagnosed at age <60 years (Statement No. 11). The gene discussed is ERBB2; the disease is Familial prostate cancer.